Utah Code 26B-7-121. Sickle cell disease
Current as of: 2024 | Check for updates
|
Other versions
In collaboration with the Medicaid program as defined in Section 26B-3-101, the Drug Utilization Review Board created in Section 26B-3-302, the Health Data Committee created in Section 26B-1-413, the Office of Health Disparities Reduction created in Section 26B-7-114, and others within the department, the Division of Population Health created in Section 26B-1-204 shall:
(1) review and develop recommendations for improving the surveillance, screening, diagnosis, and treatment of sickle cell disease among residents of the state; and
Terms Used In Utah Code 26B-7-121
- State: when applied to the different parts of the United States, includes a state, district, or territory of the United States. See Utah Code 68-3-12.5
(2) report the recommendations to the Health and Human Services Interim Committee before July 1, 2024.